[go: up one dir, main page]

GB201911066D0 - T cell therapy - Google Patents

T cell therapy

Info

Publication number
GB201911066D0
GB201911066D0 GBGB1911066.7A GB201911066A GB201911066D0 GB 201911066 D0 GB201911066 D0 GB 201911066D0 GB 201911066 A GB201911066 A GB 201911066A GB 201911066 D0 GB201911066 D0 GB 201911066D0
Authority
GB
United Kingdom
Prior art keywords
cell therapy
therapy
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1911066.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Achilles Therapeutics PLC
Original Assignee
Achilles Therapeutics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achilles Therapeutics PLC filed Critical Achilles Therapeutics PLC
Priority to GBGB1911066.7A priority Critical patent/GB201911066D0/en
Publication of GB201911066D0 publication Critical patent/GB201911066D0/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
GBGB1911066.7A 2019-08-02 2019-08-02 T cell therapy Ceased GB201911066D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB1911066.7A GB201911066D0 (en) 2019-08-02 2019-08-02 T cell therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1911066.7A GB201911066D0 (en) 2019-08-02 2019-08-02 T cell therapy

Publications (1)

Publication Number Publication Date
GB201911066D0 true GB201911066D0 (en) 2019-09-18

Family

ID=67809525

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1911066.7A Ceased GB201911066D0 (en) 2019-08-02 2019-08-02 T cell therapy

Country Status (1)

Country Link
GB (1) GB201911066D0 (en)

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004021995A2 (en) 2002-09-06 2004-03-18 The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
WO2011140170A1 (en) 2010-05-04 2011-11-10 Yeda Research And Development Co. Ltd. Immunotherapy using redirected allogeneic cells
WO2012065086A1 (en) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2013088114A1 (en) 2011-12-12 2013-06-20 Cell Medica Limited Process of expanding t cells
US20130287748A1 (en) 2010-12-09 2013-10-31 The Trustees Of The University Of Pennsylvania Use of Chimeric Antigen Receptor-Modified T-Cells to Treat Cancer
US20140120622A1 (en) 2012-10-10 2014-05-01 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
WO2015077607A1 (en) 2013-11-22 2015-05-28 The Board Of Trustees Of The University Of Illinois Engineered high-affinity human t cell receptors
WO2015143328A1 (en) 2014-03-20 2015-09-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor-infiltrating lymphocytes for adoptive cell therapy
WO2016191755A1 (en) 2015-05-28 2016-12-01 Adrian Bot Diagnostic methods for t cell therapy
WO2017049166A1 (en) 2015-09-17 2017-03-23 Novartis Ag Car t cell therapies with enhanced efficacy
WO2018002358A1 (en) 2016-06-30 2018-01-04 F. Hoffmann-La Roche Ag Improved adoptive t-cell therapy
WO2018081473A1 (en) 2016-10-26 2018-05-03 Iovance Biotherapeutics, Inc. Restimulation of cryopreserved tumor infiltrating lymphocytes
WO2018081789A1 (en) 2016-10-31 2018-05-03 Iovance Biotherapeutics, Inc. Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
WO2018094167A1 (en) 2016-11-17 2018-05-24 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
WO2018129332A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
WO2018129336A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
WO2018182817A1 (en) 2017-03-29 2018-10-04 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2018226714A1 (en) 2017-06-05 2018-12-13 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
WO2019012296A1 (en) 2017-07-14 2019-01-17 The Francis Crick Institute Limited Analysis of hla alleles in tumours and the uses thereof
WO2019094642A1 (en) 2017-11-08 2019-05-16 Neon Therapeutics, Inc. T cell manufacturing compositions and methods
WO2019100023A1 (en) 2017-11-17 2019-05-23 Iovance Biotherapeutics, Inc. Til expansion from fine needle aspirates and small biopsies
WO2019112932A1 (en) 2017-12-04 2019-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of enriching cell populations for cancer-specific t cells using in vitro stimulation of memory t cells

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004021995A2 (en) 2002-09-06 2004-03-18 The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US9074185B2 (en) 2009-08-28 2015-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2011140170A1 (en) 2010-05-04 2011-11-10 Yeda Research And Development Co. Ltd. Immunotherapy using redirected allogeneic cells
WO2012065086A1 (en) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
US20130287748A1 (en) 2010-12-09 2013-10-31 The Trustees Of The University Of Pennsylvania Use of Chimeric Antigen Receptor-Modified T-Cells to Treat Cancer
WO2013088114A1 (en) 2011-12-12 2013-06-20 Cell Medica Limited Process of expanding t cells
US20140120622A1 (en) 2012-10-10 2014-05-01 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
WO2015077607A1 (en) 2013-11-22 2015-05-28 The Board Of Trustees Of The University Of Illinois Engineered high-affinity human t cell receptors
WO2015143328A1 (en) 2014-03-20 2015-09-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor-infiltrating lymphocytes for adoptive cell therapy
WO2016191755A1 (en) 2015-05-28 2016-12-01 Adrian Bot Diagnostic methods for t cell therapy
WO2017049166A1 (en) 2015-09-17 2017-03-23 Novartis Ag Car t cell therapies with enhanced efficacy
WO2018002358A1 (en) 2016-06-30 2018-01-04 F. Hoffmann-La Roche Ag Improved adoptive t-cell therapy
WO2018081473A1 (en) 2016-10-26 2018-05-03 Iovance Biotherapeutics, Inc. Restimulation of cryopreserved tumor infiltrating lymphocytes
WO2018081789A1 (en) 2016-10-31 2018-05-03 Iovance Biotherapeutics, Inc. Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
WO2018094167A1 (en) 2016-11-17 2018-05-24 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
WO2018129332A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
WO2018129336A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
WO2018182817A1 (en) 2017-03-29 2018-10-04 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2018226714A1 (en) 2017-06-05 2018-12-13 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
WO2019012296A1 (en) 2017-07-14 2019-01-17 The Francis Crick Institute Limited Analysis of hla alleles in tumours and the uses thereof
WO2019094642A1 (en) 2017-11-08 2019-05-16 Neon Therapeutics, Inc. T cell manufacturing compositions and methods
WO2019100023A1 (en) 2017-11-17 2019-05-23 Iovance Biotherapeutics, Inc. Til expansion from fine needle aspirates and small biopsies
WO2019112932A1 (en) 2017-12-04 2019-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of enriching cell populations for cancer-specific t cells using in vitro stimulation of memory t cells

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ARES ET AL., COLD SPRING HARB PROTOC., vol. 2014, no. 11, 3 November 2014 (2014-11-03), pages 1139 - 48
BOA ET AL., CANCER INFORMATICS, vol. 13, no. 2, 2014, pages 67 - 82
HALEMARHAM: "THE HARPER COLLINS DICTIONARY OF BIOLOGY", 1991
KAMMERMEIER ET AL., J MED GENET., vol. 51, no. 11, November 2014 (2014-11-01), pages 748 - 55
KOBOLDT ET AL., GENOME RES., vol. 22, 2012, pages 568 - 576
LANDAU ET AL., CELL, vol. 152, no. 4, 14 February 2013 (2013-02-14), pages 714 - 26
MARDIS, ANNU REV ANAL CHEM, 2013
MEYERSON ET AL., NAT. REV. GENETIC, 2010
SINGLETON ET AL.: "DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY", 1994, JOHN WILEY AND SONS
YAP KL ET AL., CLIN CANCER RES., vol. 20, 2014, pages 6605

Similar Documents

Publication Publication Date Title
CA186123S (en) Battery
SG11202101996QA (en) Improved therapeutic t cell
PL3930031T3 (en) Battery
GB201813178D0 (en) Cell
IL288221A (en) Safe immuno-stealth cells
GB201803079D0 (en) Cell
PL3836300T3 (en) Battery
GB201900702D0 (en) Therapy
CA183317S (en) Therapy pack
GB201904971D0 (en) Cell
CA183316S (en) Therapy pack
GB201816399D0 (en) Cell
GB201807693D0 (en) Cell
GB201915526D0 (en) Modified cell
GB201918752D0 (en) New therapy
GB201906202D0 (en) Cell
GB201912191D0 (en) New therapy
GB201805918D0 (en) Cell
CA190719S (en) Battery
SG11202104087QA (en) Stem cell therapy
GB201911066D0 (en) T cell therapy
GB202105119D0 (en) T cell therapy
GB202006221D0 (en) T cell therapy
GB201919017D0 (en) Cell
GB201918906D0 (en) Cell

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)